Memel Biotech

Memel’s knowhow covers all aspects of advanced therapy design, trial and manufacture, plus relevant regulatory constraints.  🤝 We understand that our partners seek not just expertise, but also a supportive and agile approach to tackle the intricate challenges advanced therapy solutions face moving from research to successful commercialization. 🇪🇺 Our understanding of local market dynamics can help deliver solutions tailored for the European market and smooth collaborations for non-European companies. Get in touch and learn how our scalable solutions can help advance your project! 👉 info@mememelbiotech.com #advancedtherapies #CDMO

Last week, our Business Development Director, Karolina Karl, attended #BIO2024 in San Diego. It was an exciting week filled with fruitful meetings with existing partners, potential clients, and other industry stakeholders. We at Memel are thrilled to be part of the forefront of #cellandgene therapy innovation. By fostering collaborations and contributing to the development and manufacturing of these cutting-edge therapies, we are committed to driving #progress in the industry.

At Memel Biotech, our vision is clear: a world where life-saving advanced therapies are not just exceptional breakthroughs but routine treatments.  #Advancedtherapies represent the pinnacle of biomedical innovation, harnessing cutting-edge technology to tackle diseases that were once thought untreatable. Yet, their complexity presents significant practical and financial challenges. The path to developing these therapies involves intricate technological processes that can be daunting for any organization, big or small. This is where the necessity for expert partnerships comes into play. At Memel, we provide the agile and comprehensive support that manufacturers need to navigate the complexities of bringing advanced therapies to the market.  👉 Schedule a call to learn more about our expertise, info@memelbiotech.com, or contact our Director of Business Development, Karolina Karl, directly. #CDMO

It’s the last day of #BIO2024 and what a fantastic event it’s been! It’s been great to connect with partners, both new and old, and hear from so many expert speakers. There’s still time to meet our team. Come and say hello at the Lithuanian stand or reach out directly to our Business Development Director, Karolina Karl. #CDMO #ClinicalTrials #DrugDevelopment #ATMP #RegulatorySupport

Our Business Development Director, Karolina Karl, will be at BIO, June 3-6, San Diego. We are looking forward to a busy event and the chance to connect with current partners and new customers. If you are attending and would like to learn how Memel can help seamlessly progress your advanced therapy project with an agile partnership founded on comprehensive services and close communication, then please PM Karolina to schedule a meeting. #BIO24 #CDMO #advancedtherapies

🇪🇺 With our extensive experience and network of partners, Memel helps companies navigate the complex European regulatory landscape. We offer comprehensive regulatory support, ensuring your products meet all safety and efficacy standards through every phase of development. ✅ Clinical Trials Support: From Phase I-IV  ✅ Drug Development Consulting: Accelerate your early and pre-clinical phases  ✅ ATMP Regulatory Affairs: Get expert guidelines on both EMA and FDA regulations  ✅ State Medicines Agency Approvals: Navigate complex approvals processes     Contact us to learn how we can help push your ATMPs smoothly towards market authorization: info@memelbiotech.com  #ClinicalTrials #DrugDevelopment #ATMP #RegulatorySupport 

Our CEO Agne Vaitkeviciene will be at BIO, June 3-6, San Diego. We are looking forward to a busy event and the chance to connect with current partners and new customers.  If you are attending and would like to learn how Memel can help seamlessly progress your advanced therapy project with an agile partnership founded on comprehensive services and close communication, then please PM Agne to schedule a meeting. #BIO24 #CDMO #advancedtherapies

We are pleased to announce the strategic collaboration with Korean company THERABEST on Developing Exosome-Based and other innovative cell therapies. Thank you Verslo žinios for sharing the news. 🤝 The full article is available via: https://lnkd.in/dXzPeAp9 _____________ Džiaugiamės pasirašydami strateginę bendradarbiavimo sutartį su korėjiečių įmone THERABEST, su kuria kartu vykdysime egzosomų bei inovatyvius ląstelių terapijos tyrimus. Ačiū Verslo žinios už dėmesį. 🤝 Plačiau: https://lnkd.in/dXzPeAp9

We are very happy to have contributed to a new expert article in Biocompare exploring the optimal processes for exosome isolation. Agne Vaitkeviciene, Memel’s Co-Founder and CEO, comments, ‘Exosomes are undeniably complex and pose manufacturing and delivery challenges. However, they represent a dynamic field with potential to revolutionize multiple medical areas.’   At Memel Biotech, we're actively collaborating with partners like Therabest to refine exosome R&D and enhance isolation techniques. Our cutting-edge facility in Lithuania, launched this year, is equipped to produce high-quality, GMP-compliant exosomes for optimal therapeutic and diagnostic solutions. Read the article for deeper insights or reach out to explore our exosome solutions further: https://lnkd.in/ewTS3a_w #CDMO #exosomes

  📢 Team News!   We are delighted to welcome Bengt Carlberg to Memel. With a wealth of experience in biotechnology and a track record of success in manufacturing and quality management, Bengt joins Memel as our Director of Manufacturing.   Bengt has extensive expertise in operations, quality control and compliance, and has worked with interdisciplinary teams to obtain manufacturing authorization and GMP certification for clinical batch production. This background, along with certifications in GMP and effective documentation practices, will help further ensure that our own manufacturing operations conform to the very highest standards.   Bengt comments, ‘I firmly believe that the ATMP field will be the future of medical treatments. I am impressed by the leadership team at Memel and am very excited to bring my knowledge to the company to help facilitate its mission of making advanced therapies reality!'   🇱🇹 To read more about Bengt's appointment and Memel Biotech in Lithuanian, please read the excellent coverage in Verslo žinios: https://lnkd.in/dUH9bbzX #celltherapies #CDMO #manufacturingexcellence